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Abstract
Background: Trachoma, a neglected tropical disease, is caused by ocular infection with Chlamydia trachomatis (Ct).
The World Health Organization (WHO) recommends three annual rounds of community mass drug treatment with
azithromycin (MDA) if the prevalence of follicular trachoma in 1–9 year olds (TF1–9) exceeds 10% at district level to
achieve an elimination target of district-level TF1–9 below 5% after. To evaluate this strategy in treatment-naïve trachoma-
endemic island communities in Guinea Bissau, we conducted a cross-sectional population-based trachoma survey on four
islands. The upper tarsal conjunctivae of each participant were clinically assessed for trachoma and conjunctival swabs were
obtained (n = 1507). We used a droplet digital PCR assay to detect Ct infection and estimate bacterial load. We visited the
same households during a second cross-sectional survey and repeated the ocular examination and obtained conjunctival
swabs from these households one year after MDA (n = 1029).
Results: Pre-MDA TF1–9 was 22.0% (136/618). Overall Ct infection prevalence (CtI) was 18.6% (25.4% in 1–9 year
olds). Post-MDA (estimated coverage 70%), TF1–9 and CtI were significantly reduced (7.4% (29/394, P < 0.001)
and 3.3% (34/1029, P < 0.001) (6.6% in 1–9 year olds, P < 0.001), respectively. Median ocular Ct load was reduced from
2038 to 384 copies/swab (P < 0.001). Following MDA cases of Ct infection were highly clustered (Moran’s I 0.27, P < 0.
001), with fewer clusters of Ct infection overall, fewer clusters of cases with high load infections and less severe disease.
Conclusions: Despite a significant reduction in the number of clusters of Ct infection, mean Ct load, disease severity
and presence of clusters of cases of high load Ct infection suggesting the beginning of trachoma control in isolated
island communities, following a single round of MDA we demonstrate that transmission is still ongoing. These detailed
data are useful in understanding the epidemiology of ocular Ct infection in the context of MDA and the tools
employed may have utility in determining trachoma elimination and surveillance activities in similar settings.
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Background
Chlamydia trachomatis is the leading infectious cause of
blindness globally [1–3]. Trachoma is caused by infec-
tion with ocular strains of C. trachomatis and manifests
as distinct clinical syndromes, beginning with an acute
self-limiting kerato-conjunctivitis which may progress to
chronic inflammatory disease with subsequent conjunc-
tival scarring and blinding sequelae.
The World Health Organization (WHO) advocates the
implementation of the SAFE strategy (Surgery for trich-
iasis, Antibiotics for active infection, Facial cleanliness to
prevent disease transmission and Environmental im-
provement to increase access to water and sanitation)
for trachoma elimination. Mass drug treatment with azi-
thromycin (MDA) to entire communities aims to treat
individual cases of infection and reduce the reservoir of
infection, interrupting transmission within communities.
Repeated episodes of conjunctival infection with C.
trachomatis are thought to be required to cause the
blinding sequelae of trachoma [2, 4]. Community-wide
MDA, as part of the SAFE strategy, therefore aims to
interrupt transmission, thus reducing the number of in-
fections that each individual is exposed to and eliminate
blinding trachoma as a public health concern [2, 5].
The WHO recommends between three and five annual
rounds of MDA if the baseline prevalence of follicular
trachoma in 1–9 year olds (TF1–9) at district level is
between 10 and 39%, and at least five annual rounds of
MDA if TF1–9 ≥ 40%, to achieve a reduction of TF1–9 to
below 5% following treatment [5, 6]. These recommen-
dations were made in 2010 after previous guidance [7]
was found to be insufficient to eliminate trachoma.
According to WHO guidance, trachoma control pro-
grammes should aim to administer antibiotics to at least
80% of the population. Following completion of MDA
an impact survey is recommended, the results from the
impact survey informing decisions about continuing
treatment or conducting surveillance. There are conflict-
ing data from trachoma-endemic communities on the
optimal duration and mode of administration required
to achieve the elimination target.
Oral azithromycin, even as a single dose delivered as a
mass administration to communities, has significantly
reduced the burden of active disease and in some popu-
lations has eliminated infection with C. trachomatis en-
tirely [8]. However, the evidence-base relating to optimal
frequency of MDA that will be effective in eliminating
trachoma is not fully understood and may vary between
settings [9].
In trachoma-endemic populations with an extremely
high baseline prevalence of TF1–9, despite high coverage
of MDA under research study conditions, levels of infec-
tion and disease, although reduced, can persist or return
to pre-treatment levels. Longitudinal studies in Tanzania
suggest that with present WHO protocols, hyperen-
demic countries may need yearly mass treatment for
over ten years, which has significant economic and
logistic impact on national trachoma programmes, non-
government organisations and donors of azithromycin
[10]. Similarly in Ethiopia, despite more than seven an-
nual rounds of treatment in some regions showing that
the prevalence of disease and infection can be reduced,
but that on cessation of treatment, disease and infection
return to baseline prevalence levels [11]. Despite
adequate MDA coverage in line with WHO recommen-
dations, disease elimination at 18 months post-MDA
may not be sustained and re-emergence of disease
within households has been demonstrated [12].
In some regions where annual treatment appears to
have had little impact, even biannual treatment that has
been implemented under research study conditions has
failed to reduce TF prevalence in 1–9 year olds to less
than 5% [13]. These data are supported by findings from
a recent study, suggesting that extended MDA timelines
may be required to interrupt transmission to meet
elimination targets [14].
The dynamics of C. trachomatis transmission, particularly
in the context of MDA, is complex and not well under-
stood. Trachoma endemicity is likely to be important, as
disease can disappear spontaneously from hypoendemic
(TF1–9 5–10%) communities [15–19] or disappear after a
single round of MDA [8, 19]. In meso-endemic (TF1–9 10–
20%) populations disease prevalence may stabilize following
MDA [12], and in hyper-endemic (TF1–9 > 20%) popula-
tions disease and infection persist despite multiple rounds
of MDA [12].
The trachoma-endemic populations of the Bijagós Ar-
chipelago of Guinea-Bissau we have observed a strong
association between C. trachomatis bacterial load and
disease severity with spatial clustering of high load infec-
tions [20, 21]. In the current study we sought to assess
the impact of a single round of MDA in these isolated
treatment-naïve island communities on the prevalence
of clinical trachoma and ocular C. trachomatis infection
and investigate its effect on C. trachomatis load, disease
severity and spatial clustering of C. trachomatis infection
one year following MDA.
Methods
Study design and study population
The cross-sectional population-based trachoma survey
methodology and this study population have been de-
scribed previously [20–25]. Briefly, we used first stage
cluster random sampling with geospatial representation
on four islands at village-level to randomly select house-
holds for inclusion in the survey at baseline. A sample
size of 1000 (including a design effect of 2 to account
for anticipated household clustering) yields adequate
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power to estimate TF1–9 5% ± 3% precision [26]. Two
hundred and ninety-three households from all 38 vil-
lages were enrolled in the survey at baseline. Data were
geo-coded at household and village level [20, 21]. One
year following MDA we sought to follow up the house-
holds enrolled at baseline. A de facto census of each
household was conducted at baseline and follow-up,
from which individuals were enrolled.
Clinical examination and conjunctival sampling
Clinical examination and conjunctival sampling were
conducted at baseline and one year following treatment
using standardised methods [20, 23]. A single validated
physician examiner assessed each participant using the
WHO simplified [27] and modified FPC [5] grading sys-
tems. In the modified FPC system, follicles (F), papillary
hypertrophy (inflammation) (P) and conjunctival scar-
ring (C) are each assigned a separate grade from 0 to 3.
FPC grades of F2/3 or P3 equate to a diagnosis of active
trachoma [TF (Trachomatous inflammation-Follicular)
or TI (Trachomatous inflammation-Intense) by the
WHO simplified system] and a grade of C2/3 (and in
some cases C1) equates to a diagnosis of TS (Trachoma-
tous Scarring). Clinical grading of the upper tarsal
conjunctivae was conducted in the field as described
previously [20–23]. The trachoma grader achieved an in-
ter grader agreement (Cohen’s Kappa) score of > 0.9
against an international expert trachoma grader. Samples
were taken using a polyester-tipped swab from the left
upper tarsal conjunctiva of each participant using a well-
tolerated standardized procedure [20–23]. Quality
control swabs (pre-marked and drawn at random from
the swab dispenser in the field) were passed 10 cm in
front of the eye but without touching the eye were col-
lected and treated in the same way as the conjunctival
swabs for field and laboratory quality control. Our
ddPCR assay enabled us to detect a human target (Homo
sapiens RNase P/MRP 30-kDa subunit (RPP30) gene) to
ensure that control swabs had not come into contact
with the conjunctival surface and that swabs collected
from participants were adequate samples (using strict
minimum RPP30 detection criteria as described
previously [22]). We found no evidence of cross-
contamination using these methods; all control swabs
were negative for C. trachomatis DNA and all conjunc-
tival specimens were deemed adequate for inclusion in
the analysis.
Community mass treatment
A single height-based dose of oral azithromycin was
offered by the national trachoma control programme
distribution teams to all individuals in all communities
participating in the study in accordance with WHO and
national policy. Alternative treatment with tetracycline
eye ointment was offered if there were contraindications
to treatment with azithromycin. District-level coverage
was estimated by the national trachoma control
programme following the MDA using data from their
MDA treatment registers and the most recent Electoral
Census (2009).
Detection and quantitation of C. trachomatis
DNA was extracted from swabs using QIAamp DNA Mini
kit (Qiagen, Manchester, UK) and C. trachomatis DNA
was detected and quantitated using droplet digital PCR
(ddPCR) (Bio-Rad Laboratories, Hemel Hempstead, UK)
as described previously [20, 22, 23]. Briefly, C. trachomatis
plasmid-based ddPCR was used to detect DNA and diag-
nose infection and a single-copy pathogen chromosomal
gene (omcB) was used to estimate pathogen load in each
plasmid-positive sample [22, 23]. Estimated quantities of
omcB (C. trachomatis load) are expressed as copies/swab.
Statistical analysis
Chlamydia trachomatis quantitation data were processed
as described previously [22, 23]. Data were double entered
into a customised database (Microsoft Access 2007) and
discrepancies resolved through source documents. Data
were cleaned and analysed in STATA 13 (Stata Corpor-
ation, College Station, Texas USA). Statistical significance
was determined at the 5% level.
We estimated the variance due to between-household,
village and island clustering using null models for both ac-
tive trachoma and C. trachomatis infection adjusted for
age and gender in multivariable null models including all
three cluster variables as previously described [22].
We examined trachoma and C. trachomatis infection
prevalence data at baseline and follow-up using a Chi-
square test of proportions. Chlamydia trachomatis load
data were loge-transformed where indicated. Median
load comparisons were made between baseline and
follow-up using Kruskall-Wallis test. Associations
between load and detailed clinical phenotype (defined by
F and P scores using the modified FPC trachoma grading
system) were examined using multivariable mixed effects
linear and logistic regression models accounting for
clustering detected in previous studies [20, 21] and
adjusting for household C. trachomatis infection status
at baseline in the follow-up analysis.
Geo-coded data were projected into UTM Zone 28 N
and analysed in ArcGIS 10.1 (ESRI Inc., USA) [21]. A
statistical measure of clustering (Moran’s I) was calcu-
lated at baseline and follow-up to evaluate the effect of
MDA on the global spatial distribution of active trach-
oma and C. trachomatis infection. A local indicator of
spatial association (Local (Anselin) Moran’s I) was used
to identify clusters and outliers of C. trachomatis infec-
tion by load at baseline and follow-up. This method
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detects statistically significant clusters or outliers related
to C. trachomatis load based on the calculation of z-
scores for the distribution. Cluster types identified
(relative to their z-score and P-value) include HH (high
loads associated with other high loads), LL (low loads as-
sociated with other low loads), HL (a high load outlier
associated with other predominantly lower loads) and
LH (a low load outlier associated with other predomin-
antly high loads). The geostatistical methods used are
discussed fully elsewhere [21]. Briefly, we used the zone
of indifference to define adjacency. This method as-
sumes that each observation (individual C. trachomatis
load) has local influence that decreases with distance be-
yond a critical distance cut-off, resulting in an adapted
model of impedance, or distance decay, such that all
features have an impact on all other features, but this
impact decreases with distance. The crucial cut-off used
in this study is derived from the distance over which
spatial autocorrelation occurs in these data and relates
to the village boundaries, assuming impedance as
described above [21].
Results
Prevalence of trachoma and C. trachomatis infection
Participant enrolment and follow-up are illustrated in
Fig. 1. MDA was conducted following the baseline
survey and coverage was estimated at 70% (using
district-level data provided by the national trachoma
control programme) across the study islands. Socio-
demographic characteristics did not significantly differ
between individuals seen at baseline or at follow-up,
nor were population-based estimates of the prevalence
of scarring trachoma (TS) and trachomatous trichiasis
(TT) (Table 1). The prevalence of TF and ocular C.
trachomatis infection were statistically significantly re-
duced following treatment (Table 2). The prevalence
of TF in 1–9 year olds was reduced from 22.0% (95%
confidence interval, CI: 18.9–25.5%) to 7.4% (95% CI:
4.8–9.9%) (P < 0.001). The prevalence of TI in this age
group was also reduced: from 2.9% (95% CI: 1.4–4.1%) to
1.5% (95% CI: 0.3–2.7%). The prevalence of ocular C. tra-
chomatis infection was reduced in the population from
18.6% to 3.3% (P < 0.001) and in 1–9 year olds from 25.4%
to 6.6% (P < 0.001). Figure 2 shows the household preva-
lence of C. trachomatis infection in 1–9 year olds in the
households seen at both time points demonstrating that
the follow-up prevalence is much reduced compared to
baseline in the majority of households. However 13% (37/
293) households were lost to follow-up, and of those al-
most half (18/37) were households where C. trachomatis
infection was detected in 1–9 year olds at baseline.
Clustering of active trachoma and C. trachomatis infection
There was evidence of increased clustering at follow-
up of active trachoma and C. trachomatis infection at
village-level and infection at household level (Table 3).
The Moran’s I for C. trachomatis infection at baseline
was 0.06 (z = 2.10, P = 0.0353) and 0.27 (z = 3.85, P =
0.0001) at follow-up indicating increased clustering
following MDA.
Chlamydia trachomatis ocular load and disease severity
Median estimated load of C. trachomatis infection in in-
fected individuals was significantly reduced from 2038
omcB copies/swab to 348 omcB copies/swab (χ2 = 6.21,
P = 0.0127) (Fig. 3). At follow-up almost all infections
Fig. 1 Enrolment of participants at baseline and follow-up one year after community mass treatment for trachoma control. Community mass
treatment was distributed in accordance with WHO and national trachoma control policies. Zithromax® was donated by Pfizer Inc. through the
International Trachoma Initiative
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occurred in children under the age of 10 years, with 59%
(20/34) occurring in children aged 0–5 years. At baseline
a greater proportion of individuals with TS or normal
conjunctivae were infected, indicating that infection was
more widely spread in the population (Fig. 4).
In those with C. trachomatis infection, inflammatory
disease was less severe at follow-up, most markedly
with respect to conjunctival inflammation. There was
a shift from higher proportions of P2 and P3 scoring
disease at baseline to greater proportions of P0 and
P1 scoring disease at follow-up (Fig. 5). However,
age-adjusted mixed effect linear regression models
accounting for household clustering and household C.
trachomatis infection status at baseline demonstrate
that a strong association remains between C. tracho-
matis load and conjunctival inflammation (P score),
though the association is weaker at follow-up (ORadj
11.65, 95% CI: 1.89–71.76) compared to baseline
(ORadj 27.6, 95% CI: 6.8–111.8) (Table 4).
Spatial clustering of high load C. trachomatis infections
Maps were generated using the local Moran’s I statistic.
These demonstrated clustering of C. trachomatis infec-
tion by load and found that at baseline there were a
larger number of clusters of high load infections (HH
clusters) than at follow-up. High load outliers (HL) were
not present at follow-up. The HH clusters present at
follow-up were at different locations compared to
baseline. One HH cluster at follow-up was present in a
location where there was an HL outlier prior to MDA. A
second HH cluster was located where there was previ-
ously no clustering related to bacterial load. Clustering
of low load (LL clusters) infections was not evident at
either time point. Cluster-outlier maps at baseline and
follow-up are presented in Fig. 6. The minimum value of
C. trachomatis load observed within any HH cluster in
this data set is ~10,000 omcB copies/swab irrespective of
time point.
Table 1 Study population characteristics at baseline and follow-up at one year
Baseline nb Follow-up nb
Median age (years) (IQRa) 13 (5–32) 1507 12 (5–35) 1033
Female 58% 869 63% 648
Age group
0–5 years 28% 416 28% 288
6–10 years 16% 250 17% 180
11–15 years 11% 157 10% 113
> 15 years 45% 684 45% 452
Conjunctival scarring (TSc)
Prevalence overall (95% CI) 23.8 (21.6–25.9) 357/1502 30.5 (27.7–33.3) 313/1026
Prevalence by age group (95% CI)
0–5 years 2.7 (1.1–4.2) 11/414 2.1 (0.4–3.7) 6/288
6–10 years 2.8 (0.8–4.8) 7/250 5.6 (2.2–9.1) 10/177
11–15 years 11.5 (6.5–16.4) 18/157 18.9 (11.6–26.2) 21/111
> 15 years 47.2 (43.5–51.0) 321/680 61.3 (56.8–65.8) 276/450
Trachomatous trichiasis (TT>15
d ) (95% CI) 3.5 (2.1–4.9) 24/680 5.1 (3.1–7.1) 23/450
aIQR, interquartile range
bDenominator where indicated
cWHO Simplified Trachoma Grading System (28); TT>15 reflects TT in those over the age of 15 years
dCI, confidence interval
Table 2 The effect of community mass treatment with
azithromycin on the prevalence of active trachoma and ocular
C. trachomatis infection
Clinical category Prevalence (%) (95% CIa) Prevalence (%) (95% CIa)
Baseline n Follow-up n
TF1–9
b 22.0 (18.9–25.5) 136/618 7.4 (4.8–9.9)* 29/394
TI1–9 2.9 (1.4–4.1) 18/618 1.5 (0.3–2.7) 6/394
Ctall
c 18.6 (16.7–28.8) 280/1502 3.3 (2.2–4.4)** 34/1029
Ct1–9 25.4 (22.0–28.8) 157/618 6.6 (4.1–9.0)*** 26/395
aCI, confidence interval
bTF1–9, TF (Trachoma-Follicular) in 1–9 year olds; TI1–9 = TI (Trachoma-Intense
Inflammatory) in 1–9 year olds
cCt, C. trachomatis infection in the population overall and in 1–9 year olds 293
households were included at baseline and 254 at follow-up. Of the households
lost to follow-up, 18 had C. trachomatis detected in children aged 1–9 years
within the household at baseline. C. trachomatis infection status of the house-
hold at baseline was adjusted for in the follow-up analysis
*P < 0.0001; Chi-square test, χ2 = 37.5, df = 1, difference 14.6% (95%
CI: 10.2–18.8%)
**P < 0.0001; Chi-square test, χ2 = 131.7, df = 1, difference 15.3% (95%
CI: 13.0–17.6%)
***P < 0.0001; Chi-square test, χ2 = 57.5, df = 1, difference 18.8% (95%
CI: 14.3–23.1%))
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Discussion
The WHO recommends that MDA aim for 80%
coverage to be considered adequate for trachoma con-
trol programmes [5]. However, due to the significant
logistic challenges that exist in this remote area it
was only possible to deliver MDA to an estimated
70% of the population. Our data suggest that in these
island communities, despite initial high disease and
infection prevalence and suboptimal MDA coverage,
we observed a dramatic reduction in prevalence of
both TF in 1–9 year olds and ocular C. trachomatis
infection (overall and in 1–9 year olds) one year after
MDA. This type of dramatic reduction has been ob-
served previously in treatment-naïve settings following
azithromycin MDA [28].
Active trachoma and C. trachomatis infection (par-
ticularly those with the highest bacterial loads) were
most prevalent in children under 10 years of age at
both baseline and follow-up. Following MDA C. tra-
chomatis infection virtually disappeared in adults and
was reduced in those with scarred or normal conjunc-
tivae. The presence of C. trachomatis infection across
all age groups and clinical phenotypes at baseline is
likely to represent the distribution typical of chronic
endemic trachoma before MDA [29]. The reduction
in the prevalence of infection and change in distribu-
tion by age and disease suggests a shift in the epi-
demiology of ocular C. trachomatis infection in these
communities and may mark the beginning of control
of transmission.
The significantly lower median ocular C. trachomatis
load following MDA was consistent with findings from
other studies suggesting that from 2 to 12 months
following MDA the prevalence and load of infections
remain low [12].
The number of clusters of high load infections de-
tected using local spatial statistics was reduced and there
was an absence of high load outlying infections amidst
other low load infections after MDA. This phenomenon
may be due to reduced chlamydial diversity in the
Fig. 2 Prevalence of C. trachomatis infection in 1–9 year olds by household at baseline and follow-up. The grey bars show the prevalence
of C. trachomatis infection (detected by ddPCR) in individual households at baseline. The black squares denote the prevalence of C.
trachomatis infection in the same households at follow-up. The y-axis refers to the prevalence of C. trachomatis infection in 1–9 year olds.
13% (n = 37) households were not included at follow-up. Of those, almost half (n = 18) were households where C. trachomatis infection
was detected in children aged 1–9 years at baseline
Table 3 Clustering of active trachoma and C. trachomatis infection
Active trachoma Ct infection
Cluster level CEBaseline
a (95% CI SE) CEFollow-up 95% CI SE) CEBaseline
a (95% CI SE) CEFollow-up (95% CI SE)
Household 1.08 (0.79–1.48) 0.89 (0.85–0.95) 1.35 (1.08–1.68) 1.52 (0.85–2.74)
Village 0.76 (0.50–1.14) 1.05 (0.56–1.96) 0.89 (0.65–1.21) 1.04 (0.56–1.96)
Island 0.47 (0.15–1.49) 0.34 (0.08–1.37) 0.42 (0.17–1.00) 0.19 (0.01–5.76)
aCE, cluster estimates obtained from age-adjusted mixed effects regression models for active trachoma and Ct (C. trachomatis) infection at baseline and follow-up.
95% CI (confidence intervals) of the SE (standard error) are quoted. Mixed effects models including all three cluster levels showed household to have the strongest
effect. All cluster estimates were significant at the 1% level (Wald Chi2)
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population following MDA. The role of chlamydial strain
diversity in transmission is unclear but greater diversity
is likely to represent more successful transmission.
There is some evidence that following MDA in other
settings the number of C. trachomatis strains defined by
ompA genotyping [30] or multi-locus sequence typing
[31] was substantially reduced.
These data support the previous suggestion that C.
trachomatis load is important in transmission of infec-
tion and its maintenance in the population [18, 21]. At
both time points the minimum C. trachomatis load that
we observed within an HH cluster was ~10,000 omcB
copies/swab, supporting the hypothesis that there may
be a threshold load important to sustain transmission, as
suggested by Chidambaram et al. [32]. The change from
an HL outlier prior to MDA to an HH cluster, and the
appearance of a new HH cluster were there was
previously none, following treatment suggests that there
is likely to be ongoing transmission within this popula-
tion. This particular location has a mobile population,
being populated by fishermen and their families from
Guinea Conakry, Sierra Leone and other islands on the
archipelago. There are limited amenities in this settle-
ment and it is possible that infection has been reintro-
duced. Introduction of infection following migration
events has been documented in The Gambia [33]. In
general, these island communities less susceptible to in-
migration due to their isolated geographical location and
therefore represent a unique opportunity to evaluate the
effect of MDA in treatment-naïve trachoma-endemic
populations.
Clustering of disease and infection was more apparent
following MDA. Increased clustering of cases of C. tra-
chomatis infection in treated communities has been
Fig. 3 Reduction in median C. trachomatis load in ocular C. trachomatis infection following community mass treatment with azithromycin.
Box-and-whisker plots showing the median C. trachomatis load (omcB copies/swab) from individuals with conjunctival infection at
baseline and follow-up
Fig. 4 The effect of community mass treatment with azithromycin on ocular C. trachomatis load by age and clinical phenotype before treatment (a)
and at one year following treatment with oral azithromycin (b). Clinical phenotype is defined using the WHO simplified grading system [27]
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described elsewhere [34]. In this study the strongest
clustering of C. trachomatis infection was present at vil-
lage level following MDA. This may be relevant in the
context of previous spatial analyses conducted in this
population suggesting that the village may an important
unit of transmission in addition to the household in
these communities and that the dynamics of transmis-
sion are different before and after MDA [21].
We used the detailed conjunctival grading system to
investigate associations between infection, bacterial load
and disease severity following MDA. A strong associ-
ation between C. trachomatis load and inflammatory
trachoma has been described previously [21, 28, 35].
The reduced association between infection and P score
following MDA may reflect the decreased burden of
circulating infection and decreased infection loads. It is
likely that repeated episodes of infection are reduced fol-
lowing MDA due to a decrease in circulating C. tracho-
matis and subsequently reduced transmission. Moreover,
in populations undergoing MDA there is evidence that
clinical signs of trachoma become less specific for C. tra-
chomatis infection [36, 37], suggesting that only the
more severe phenotypes remain predictive of C. tracho-
matis infection. Azithromycin exhibits immunomodula-
tory effects that may be associated with reduced levels of
inflammation [38], although at one year after a single
dose this effect is unlikely to play a major role.
Although these are interesting data, the analysis is
limited by the potential impact of loss to follow-up
after MDA. 13% of households were not available at
follow-up, and almost half of these were households
where we found individuals with C. trachomatis infec-
tion at baseline. Clearly this may represent responder
bias. The characteristics of the population in terms of
age distribution, gender and chronic sequelae (trach-
omatous trichiasis) suggest that the follow-up sample
is adequately representative of the baseline sample.
However, the prevalence of conjunctival scarring in
Fig. 5 The effect of community mass treatment with azithromycin on conjunctival inflammation in individuals with ocular C. trachomatis
infection. Proportion of individuals with conjunctival inflammation (P score 0–3 according to the modified FPC grading system at baseline (a) and
follow-up (b)
Table 4 The effect of community mass treatment with azithromycin on associations between disease severity and C. trachomatis
bacterial load in individuals with ocular C. trachomatis infection
Baseline (n = 184) Follow-up (n = 34)
Clinical phenotype n ORadj (95% CI) P-value n ORadj (95% CI) P-value
F-score
F0 89 – 11 –
F1 22 1.67 (0.48–5.78) 0.417 5 2.15 (0.29–15.72) 0.450
F2 27 1.84 (0.60–5.68) 0.287 6 3.56 (0.24–52.19) 0.354
F3 42 6.16 (1.97–19.26) 0.002 9 17.71 (2.65–118.47) 0.003
P-score
P0 48 – 10 –
P1 68 6.15 (2.47–15.31) < 0.001 13 1.25 (0.31–4.97) 0.753
P2 45 21.74 (6.82–69.32) < 0.001 3 1.16 (0.18–7.62) 0.875
P3 24 27.61 (6.81–111.80) < 0.001 5 11.65 (1.89–71.76) 0.008
Note: Age-adjusted multivariable mixed effects linear regression analysis of loge-transformed C. trachomatis load (omcB copies/swab) accounting for household
clustering and C. trachomatis infection status at baseline (OR 0.98, 95% CI: 0.25–3.86, P = 0.975). F- and P-scores were assigned using the modified FPC grading
system [5]. Individuals may appear in multiple clinical grading categories. P-value is for the Wald Chi2
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the cohort at follow-up was higher, possibly due to
selective drop out of less severely affected individuals.
This may affect the overall prevalence of C. tracho-
matis infection found at follow-up, as the prevalence
of infection in conjunctival scarring is likely to be
higher than in those with no clinical signs of tra-
choma [39]. Additional limitations of the study in-
clude the programmatic implementation of SAFE. We
did not evaluate the implementation of the ‘F’ and ‘E’
components of SAFE to improve hygiene and sanita-
tion alongside MDA in this study. Nor did we have
access to accurate MDA coverage estimates, at indi-
vidual or household level. At the time of the study
there was limited implementation of ‘F’ and ‘E’ com-
ponents of SAFE in Guinea Bissau, but there may still
have been some effect in these communities that we
could not evaluate [40]. Evaluating C. trachomatis
load and clinical disease severity in cross-sectional
studies is limited in the assumption that the duration
of infection and the host conjunctival immune re-
sponse are present in a steady state. To fully investi-
gate the dynamics of C. trachomatis transmission
more detailed longitudinal study is required, ideally in
the context of individual or household level MDA
coverage.
Conclusions
In summary, through investigating the micro-
epidemiology of C. trachomatis infection and its
relationship with bacterial load and disease severity,
these data suggest that MDA is likely to be having a sig-
nificant impact on transmission of ocular C. trachomatis
in these communities. However, further monitoring is
required, as this geospatial analysis suggests that that
there may be on-going transmission and risk of reintro-
duction of infection to communities despite MDA. The
loss to follow-up in the population following MDA is
also a concern and may indicate that these data
underestimate the current burden of circulating ocular
C. trachomatis infection and trachoma. Further longitu-
dinal study, utilising mathematical models and high-
resolution chlamydial genotyping and geospatial analysis,
is necessary to provide a more complete picture of the
relationship between disease severity, chlamydial load,
transmission and elimination thresholds in communities
undergoing MDA. These tools may improve our under-
standing of disease pathogenesis and transmission and
may be useful in trachoma surveillance in post-MDA
settings to identify clusters of infection and thresholds of
C. trachomatis bacterial load that may be important foci
of transmission.
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